PO.ET09.10 · 实验与分子治疗
Tyrosine Kinase, Phosphatase, and Other Inhibitors
-
-
-
-
-
- 5868 5868 蛋白质组学分析与疗效评估揭示lasmotinib联合menin抑制剂对AML具有强协同抗白血病活性 Proteomic analysis and efficacy evaluation reveal strong synergistic anti-leukemic activity of lasmotinib combined with menin inhibitors for AML An-Na Moon, Hee-sun Hwang, Ky-Youb Nam, KyungMin Cha, Sang Beom Lee, ChongChul Chai, Jinsun Kwon, Kyu-Tae Kim, June H. Han, Jeong Hyeok Yoon
- 5869 5869 CGT4255的临床前特征描述：一种不影响EGFR的泛突变HER2临床开发候选药物，具有潜在同类最佳的脑渗透性 Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration Paul Larsen, Tanna Bettendorf, Abiezer Blandon, Karyn Bouhana, Richard K. Brizendine, Eric Brown, LouAnn Cable, Mark J. Chicarelli, Michelle Crow, Brad Fell, John Fischer, Jennifer Fulton, Anna Guarnieri, Jackie Harrison, Leyla Haygood, Ravi Jalluri, Vijay Kumar, Cori A. Malinky, Maralee McVean, Rob Rieger, John Robinson, Lee Stunkard, Francis Sullivan, John I. Trujillo, Logan E. Vine, Shannon Winski, Yeyun Zhou
-
- 5871 5871 firmonertinib的发现与特征描述：一种对EGFR经典突变和exon 20插入突变均具有广泛活性的新型EGFR抑制剂 Discovery and characterization of firmonertinib, a novel EGFR inhibitor with broad activity against both EGFR classical and exon 20 insertion mutations Huibing Luo, Qing Li, Qiufeng Liu, Huayong Zhou, Yuting Sun, Jerry Y. Hsu, Luna Musib, Marcin Kowanetz, Stuart Lutzker, Zineb Mounir
-
-
- 5875 5875 多激酶抑制剂olverembatinib（HQP1351）在套细胞淋巴瘤（MCL）临床前模型中有效并与BTK抑制剂acalabrutinib协同 Multikinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models Bo Peng, Zhiyan Liang, Yan Xiong, Bingxing Wu, Shujie He, Zhou Yu, Guoqin Zhai, Dajun Yang, Yifan Zhai
- 5876 5876 阻断可溶性TNF作为增强酪氨酸激酶抑制剂应答并控制HER2阳性乳腺癌转移负荷的策略 Soluble TNF blockade as a strategy to enhance tyrosine-kinase inhibitor response and control metastatic burden in HER2-positive breast cancer Sofia Bruni, Marla Ladera, Camila Jencquel, Federico Waisberg, Martin A. Rivas, Roxana Schillaci, Maria Florencia Mercogliano
- 5877 5877 BH-30643：一种新型大环非共价、突变体选择性EGFR抑制剂，解决当代EGFR TKI在耐药性和效力上的局限 BH-30643, a novel macrocyclic non-covalent, mutant-selective EGFR inhibitor, addresses the resistance and potency limitations of contemporary EGFR TKIs Ping Jiang, Wei Deng, Nancy Ling, Danan Li, Zhenping Wang, Yue Hu, Joshua Choi, Eugene Rui, Geoffrey Oxnard, Jean Cui
-
-
-
-
- 5882 5882 以结构和生物信息学驱动开发一种选择性、口服生物利用度良好的HER2小分子抑制剂（HM100714）用于癌症治疗 Structure- and bioinformatics-driven development of a selective, orally bioavailable HER2 small molecule inhibitor (HM100714) for cancer therapy Ho Yeon Nam, Sun Young Jang, Jiyoung Jeon, HyungSeok Yoo, Jooyun Byun, Soonki Park, Soye Jeon, Haemin Chon, Yu-Yon Kim, Boram Kim, Young Gil Ahn
-
-
- 5885 5885 通过NXP900抑制SRC家族激酶靶向髓源性抑制细胞(MDSC)以恢复非小细胞肺癌(NSCLC)的抗肿瘤免疫 Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity in non-small cell lung cancer (NSCLC) via SRC family kinase Inhibition with NXP900 Bobby Kaghazchi, In Hwa Um, Amber Ortiz, Enrique Podarosu, David J. Harrison, Neil Carragher, Asier Unciti-Broceta
-
- 5887 5887 可逆性与共价性HER2激酶抑制剂的抗肿瘤活性及更广泛生物学效应分析，以评估其选择性和功能活性 Profiling of reversible and covalent HER2 kinase inhibitors for anti-tumor activity and broader biological effects to evaluate selectivity and functional activity Luciano Galdieri, Steven Garner, Brogan Epkins, Emily Schultz, Daria Clucas, Pony (Yu-Ling) Lee, Chao-Di Chang, Chien-Chang Shen, Alastair J. King
-
-
